Alex Thompson CFA
Stock Analyst at Stifel Nicolaus
(4.97)
# 70
Out of 4,478 analysts
268
Total ratings
73.6%
Success rate
46.6%
Average return
Main Sectors:
Stocks Rated by Alex Thompson CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PALI Palisade Bio | Maintained: Buy | $5 | $2.04 | +145.10% | 4 | Jul 6, 2026 | |
| EVMN Evommune | Maintained: Buy | $54 | $12.36 | +336.89% | 2 | Jul 6, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | $39 → $40 | $18.99 | +110.64% | 18 | Jun 30, 2026 | |
| ORKA Oruka Therapeutics | Maintained: Buy | $150 | $83.13 | +80.44% | 10 | Jun 29, 2026 | |
| ARGX argenx SE | Maintained: Buy | $1,255 | $916.80 | +36.89% | 29 | Jun 29, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintained: Buy | $83 | $42.03 | +97.48% | 12 | Jun 29, 2026 | |
| APGE Apogee Therapeutics | Maintained: Buy | $135 → $133 | $133.48 | -0.36% | 15 | Jun 29, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $107 | $88.74 | +20.58% | 18 | Jun 22, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $28 | $17.81 | +57.22% | 6 | Jun 8, 2026 | |
| EQ Equillium | Reiterated: Buy | $5 | $2.77 | +80.51% | 2 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $49 | $38.60 | +26.94% | 16 | May 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $39 | $19.96 | +95.39% | 6 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $332 → $328 | $267.92 | +22.42% | 16 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2 → $4 | $5.49 | -27.14% | 13 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $21.34 | +87.44% | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $43 | $57.48 | -25.19% | 29 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $43 | $33.47 | +28.47% | 1 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $44 | $27.27 | +61.35% | 4 | Apr 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $65 → $120 | $93.36 | +28.53% | 11 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 → $85 | $62.31 | +36.41% | 11 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $13 → $19 | $18.88 | +0.64% | 8 | Mar 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 → $68 | $37.95 | +79.18% | 6 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $68 → $114 | $115.07 | -0.93% | 9 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $3 | $1.15 | n/a | 17 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $13.95 | n/a | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $34 | $39.79 | n/a | 1 | Aug 8, 2023 |
Palisade Bio
Jul 6, 2026
Maintained: Buy
Price Target: $5
Current: $2.04
Upside: +145.10%
Evommune
Jul 6, 2026
Maintained: Buy
Price Target: $54
Current: $12.36
Upside: +336.89%
Viridian Therapeutics
Jun 30, 2026
Maintained: Buy
Price Target: $39 → $40
Current: $18.99
Upside: +110.64%
Oruka Therapeutics
Jun 29, 2026
Maintained: Buy
Price Target: $150
Current: $83.13
Upside: +80.44%
argenx SE
Jun 29, 2026
Maintained: Buy
Price Target: $1,255
Current: $916.80
Upside: +36.89%
Crinetics Pharmaceuticals
Jun 29, 2026
Maintained: Buy
Price Target: $83
Current: $42.03
Upside: +97.48%
Apogee Therapeutics
Jun 29, 2026
Maintained: Buy
Price Target: $135 → $133
Current: $133.48
Upside: -0.36%
Spyre Therapeutics
Jun 22, 2026
Reiterated: Buy
Price Target: $107
Current: $88.74
Upside: +20.58%
Cullinan Therapeutics
Jun 8, 2026
Maintained: Buy
Price Target: $28
Current: $17.81
Upside: +57.22%
Equillium
May 28, 2026
Reiterated: Buy
Price Target: $5
Current: $2.77
Upside: +80.51%
May 25, 2026
Maintained: Buy
Price Target: $49
Current: $38.60
Upside: +26.94%
May 15, 2026
Maintained: Buy
Price Target: $36 → $39
Current: $19.96
Upside: +95.39%
May 8, 2026
Maintained: Buy
Price Target: $332 → $328
Current: $267.92
Upside: +22.42%
May 8, 2026
Maintained: Hold
Price Target: $2 → $4
Current: $5.49
Upside: -27.14%
May 7, 2026
Maintained: Buy
Price Target: $40
Current: $21.34
Upside: +87.44%
May 5, 2026
Maintained: Hold
Price Target: $43
Current: $57.48
Upside: -25.19%
May 1, 2026
Initiated Coverage: Buy
Price Target: $43
Current: $33.47
Upside: +28.47%
Apr 4, 2026
Maintained: Buy
Price Target: $44
Current: $27.27
Upside: +61.35%
Mar 10, 2026
Maintained: Buy
Price Target: $65 → $120
Current: $93.36
Upside: +28.53%
Mar 5, 2026
Maintained: Buy
Price Target: $56 → $85
Current: $62.31
Upside: +36.41%
Mar 1, 2026
Maintained: Hold
Price Target: $13 → $19
Current: $18.88
Upside: +0.64%
Feb 26, 2026
Maintained: Buy
Price Target: $58 → $68
Current: $37.95
Upside: +79.18%
Dec 15, 2025
Maintained: Buy
Price Target: $68 → $114
Current: $115.07
Upside: -0.93%
Mar 3, 2025
Downgraded: Hold
Price Target: $32 → $3
Current: $1.15
Upside: n/a
Nov 7, 2024
Reiterated: Buy
Price Target: $23
Current: $13.95
Upside: n/a
Aug 8, 2023
Initiated Coverage: Buy
Price Target: $34
Current: $39.79
Upside: n/a